Alpha 2.0
Login Register
» Authors » Raghu Venkatramanamoorthy

Raghu Venkatramanamoorthy

Explore the profile of Raghu Venkatramanamoorthy including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 14
Citations 220
Followers 0
Related Specialties
Oncology
Pulmonary Medicine
Nutritional Sciences
Top 10 Co-Authors
Lance K Heilbrun
Anthony F Shields
Philip A Philip
Mark M Zalupski
Bassel F El-Rayes
Omer Kucuk
Zora Djuric
John C Ruckdeschel
Ulka Vaishampayan
Ann Marie Ferris
Published In
J Thorac Oncol
Nutr Cancer
J Vasc Interv Radiol
Clin Lung Cancer
Skull Base
Affiliations
Soon will be listed here.
Recent Articles
1.
Participation and survival of geriatric patients in Phase I clinical trials: the Karmanos Cancer Institute (KCI) experience
Zafar S, Heilbrun L, Vishnu P, Jasti P, Venkatramanamoorthy R, Ding L, et al.
J Geriatr Oncol . 2011 Apr; 2(1):18-24. PMID: 21503272
BACKGROUND: Geriatric cancer patients (age 65 or older) comprise a majority of cancer cases in the United States, yet they are underrepresented in therapeutic clinical trials. It is therefore important...
2.
Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer
Mobayed M, Heilbrun L, Shields A, Washington T, Venkatramanamoorthy R, Philip P, et al.
Case Rep Oncol . 2010 Aug; 2(3):220-228. PMID: 20737041
BACKGROUND: Adjuvant 5-fluorouracil (5FU)-based chemo-radiotherapy is currently considered a standard of care for the treatment of gastric cancer. The impact of 5FU-based adjuvant therapy on the rate of distant recurrence...
3.
CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy
Hammad N, Heilbrun L, Philip P, Shields A, Zalupski M, Venkatramanamoorthy R, et al.
Asia Pac J Clin Oncol . 2010 Jun; 6(2):98-105. PMID: 20565421
Aims: The aim of this study was to determine the predictive role of pretreatment carbohydrate antigen 19-9 (CA19-9) measurement and its change after one cycle of gemcitabine-based therapy for response,...
4.
Sinonasal mucosal melanoma: a 13-year experience at a single institution
Narasimhan K, Kucuk O, Lin H, Heilbrun L, Carron M, Venkatramanamoorthy R, et al.
Skull Base . 2010 Jan; 19(4):255-62. PMID: 20046593
Objective: Report the experience of the Karmanos Cancer Institute with sinonasal mucosal melanoma (SNMM) in patients diagnosed between 1995 and 2007. Results: Eighteen patients, ages 31 to 85 (mean, 67),...
5.
Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer
Choi M, Heilbrun L, Venkatramanamoorthy R, Lawhorn-Crews J, Zalupski M, Shields A
Am J Clin Oncol . 2009 Oct; 33(3):257-61. PMID: 19806035
Background: Pancreatic cancer ranks as the fourth leading cause of cancer death in the United States with 5-year survival ranging from 1% to 5%. Positron emission tomography (PET) is a...
6.
Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer
Gadgeel S, Wozniak A, Ruckdeschel J, Heilbrun L, Venkatramanamoorthy R, Chaplen R, et al.
J Thorac Oncol . 2008 Nov; 3(11):1293-300. PMID: 18978565
Introduction: The utility of two-drug chemotherapy regimens in elderly or performance status (PS 2) patients with advanced non-small cell lung cancer (NSCLC) remains to be established. Preclinical studies suggested that...
7.
Effects of high fruit-vegetable and/or low-fat intervention on breast nipple aspirate fluid micronutrient levels
Djuric Z, Chen G, Ren J, Venkatramanamoorthy R, Covington C, Kucuk O, et al.
Cancer Epidemiol Biomarkers Prev . 2007 Jul; 16(7):1393-9. PMID: 17627004
Background: A change in diet is known to affect micronutrient levels in blood but to what extent diet can affect micronutrient levels in the breast is not yet well established....
8.
Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer
Wozniak A, Belzer K, Heilbrun L, Kucuk O, Gadgeel S, Kalemkerian G, et al.
Clin Lung Cancer . 2007 Jun; 8(5):313-8. PMID: 17562230
Purpose: This phase II study evaluated the efficacy and toxicity of gemcitabine/paclitaxel given every 2 weeks in patients with advanced-stage non-small-cell lung cancer. Treatment with 1 previous chemotherapy regimen was...
9.
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer
El-Rayes B, Zalupski M, Manza S, Rusin B, Ferris A, Vaishampayan U, et al.
Cancer Chemother Pharmacol . 2007 Apr; 61(2):283-9. PMID: 17429629
Background: The cyclooxygenase-2 (COX-2) enzyme plays a major role in tumor progression and resistance to chemotherapy. A Phase-II study was undertaken to determine the activity of a dose attenuated schedule...
10.
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC)
Gadgeel S, Ruckdeschel J, Heath E, Heilbrun L, Venkatramanamoorthy R, Wozniak A
J Thorac Oncol . 2007 Apr; 2(4):299-305. PMID: 17409801
Background: Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has demonstrated a response rate of 9%-18% in relapsed non-small cell lung cancer (NSCLC) patients. The probability of response to...